Wedbush Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics (NASDAQ:TVTX) had its price target lifted by equities researchers at Wedbush from $39.00 to $44.00 in a research report issued on Tuesday, MarketBeat reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price would indicate a potential upside of 7.45% from the company’s current price.

TVTX has been the topic of several other reports. JPMorgan Chase & Co. cut their target price on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research note on Tuesday. Wall Street Zen downgraded Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Piper Sandler boosted their price objective on Travere Therapeutics from $35.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and an average target price of $42.50.

Travere Therapeutics Stock Down 2.8%

Shares of TVTX opened at $40.95 on Tuesday. The company has a market capitalization of $3.78 billion, a PE ratio of -136.50 and a beta of 0.86. Travere Therapeutics has a 12 month low of $13.88 and a 12 month high of $43.31. The stock’s 50-day moving average price is $29.57 and its two-hundred day moving average price is $31.37. The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71.

Insiders Place Their Bets

In other news, insider Elizabeth E. Reed sold 44,715 shares of the business’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $41.21, for a total value of $1,842,705.15. Following the transaction, the insider directly owned 111,996 shares of the company’s stock, valued at $4,615,355.16. The trade was a 28.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider William E. Rote sold 12,446 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $32.87, for a total value of $409,100.02. Following the completion of the transaction, the insider directly owned 109,087 shares in the company, valued at $3,585,689.69. This represents a 10.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 444,127 shares of company stock valued at $15,206,744 over the last 90 days. 4.19% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TVTX. Stephens Investment Management Group LLC acquired a new position in Travere Therapeutics during the 3rd quarter worth approximately $38,232,000. State Street Corp raised its stake in Travere Therapeutics by 47.8% during the 4th quarter. State Street Corp now owns 4,756,666 shares of the company’s stock worth $181,752,000 after buying an additional 1,538,827 shares during the period. Wellington Management Group LLP raised its stake in Travere Therapeutics by 3,331.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company’s stock worth $28,715,000 after buying an additional 1,166,460 shares during the period. Fiera Capital Corp acquired a new position in Travere Therapeutics during the 4th quarter worth approximately $33,398,000. Finally, Perceptive Advisors LLC acquired a new position in Travere Therapeutics during the 2nd quarter worth approximately $12,347,000.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.